...A. We have two product launches late last year when newer for hereditary ATTR polyneuropathy was approved by the FDA in late January. B. In addition, just last week, QALSODY our treatment that we've discovered and developed and is now commercialized by our partner Biogen was approved in Europe. C. We've also had three very positive Phase 3 readouts this year, the balance study for whole resource in familial chylomicronaemia syndrome or FCS. D. Our resourcing for two indications familial chylomicronaemia syndrome with potential approval late this year, assuming priority review and then our SHTG study for a much higher, a high, highly prevalent disease indication for severe hypertriglyceridemia and starting to worsen our program for prophylactic treatment of hereditary angioedema. E. I already touched on the pure version for chronic HBV now fully enrolled with data expected in 2026 and our Ionis-FB-LRX program with Roche in IGA nephropathy, with data expected down the road and then tofersen,...
